We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2128:HKEXChina Lesso Group Holdings Limited Analysis

Data as of 2026-03-17 - not real-time

HK$6.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

China Lesso is trading around HK$6, comfortably above the 20‑day SMA (6.33) and the 50‑day SMA (5.79) while staying above the 200‑day SMA (4.89), indicating a sustained bullish trend. Support sits at HK$5.60 and the next resistance is near HK$7.14, with volume accelerating and the RSI hovering at 46.9, suggesting room for upside but also a neutral momentum reading. Technical signals are mixed: the MACD histogram is negative and the signal line is bearish, while volatility is elevated at over 42% and the beta is unusually low (≈0.1), implying limited market‑wide risk but high price swings. On the fundamentals side, the stock’s PE of 9.7 is far below the industry average of 29.4, yet the DCF‑derived fair value of HK$2.12 signals a substantial premium; a debt‑to‑equity ratio of 76.8% and total debt of HK$19 bn dwarf its cash balance of HK$3.7 bn, raising leverage concerns. The company still offers a solid 3.24% dividend yield with a modest 33% payout, while profit margins are thin (6.5% net) and revenue has contracted 8% YoY. Overall, the price reflects optimism on the dividend and sector recovery, but the valuation appears stretched relative to intrinsic estimates.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD and negative histogram
  • High short‑term volatility (42%)
  • Significant valuation gap vs DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Attractive dividend yield and sustainable payout
  • Low systematic beta reducing market risk
  • Ongoing leverage constraints limiting earnings growth

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential for sector recovery in building products
  • Value‑oriented PE relative to peers
  • High debt level requiring balance‑sheet improvement

Key Metrics & Analysis

Financial Health

Revenue Growth-8.00%
Profit Margin6.50%
P/E Ratio9.7
ROE6.40%
ROA3.97%
Debt/Equity76.83
P/B Ratio0.7
Op. Cash FlowHK$2.8B
Free Cash FlowHK$1.6B
Industry P/E29.4

Technical Analysis

TrendBullish
RSI46.9
SupportHK$5.60
ResistanceHK$7.14
MA 20HK$6.33
MA 50HK$5.79
MA 200HK$4.89
MACDBearish
VolumeIncreasing
Fear & Greed Index81.48

Valuation

Fair ValueHK$2.12
Target PriceHK$5.61
Upside/Downside-6.48%
GradeOvervalued
TypeValue
Dividend Yield3.24%

Risk Assessment

Beta0.10
Volatility42.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.